Shares of Repligen Corp. (NASDAQ:RGEN) rose 4.2% during trading on Thursday . The stock traded as high as $30.75 and last traded at $30.73, with a volume of 103,177 shares trading hands. The stock had previously closed at $29.49.

RGEN has been the subject of several recent analyst reports. Zacks Investment Research cut Repligen Corp. from a “hold” rating to a “sell” rating in a report on Wednesday, June 8th. Jefferies Group reissued a “hold” rating and issued a $28.00 price target on shares of Repligen Corp. in a report on Monday, June 13th.

The stock has a market capitalization of $1.03 billion and a PE ratio of 122.52. The firm’s 50-day moving average is $27.64 and its 200-day moving average is $25.77.

Repligen Corp. (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, August 4th. The company reported $0.16 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.03. The firm earned $29.20 million during the quarter, compared to the consensus estimate of $24.75 million. The firm’s quarterly revenue was up 35.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.11 earnings per share. On average, analysts predict that Repligen Corp. will post $0.44 earnings per share for the current fiscal year.

In other news, Director Thomas F. Ryan, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $26.60, for a total transaction of $133,000.00. Following the completion of the transaction, the director now directly owns 12,094 shares of the company’s stock, valued at $321,700.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas F. Ryan, Jr. sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 28th. The shares were sold at an average price of $24.59, for a total value of $245,900.00. Following the transaction, the director now directly owns 27,094 shares of the company’s stock, valued at $666,241.46. The disclosure for this sale can be found here.

Several institutional investors recently bought and sold shares of RGEN. Globeflex Capital L P raised its position in Repligen Corp. by 50.6% in the fourth quarter. Globeflex Capital L P now owns 36,153 shares of the company’s stock valued at $1,023,000 after buying an additional 12,153 shares during the period. Rhumbline Advisers raised its position in Repligen Corp. by 9.4% in the fourth quarter. Rhumbline Advisers now owns 57,619 shares of the company’s stock valued at $1,630,000 after buying an additional 4,970 shares during the period. California State Teachers Retirement System raised its position in Repligen Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 60,884 shares of the company’s stock valued at $1,722,000 after buying an additional 984 shares during the period. Russell Frank Co raised its position in Repligen Corp. by 12.7% in the fourth quarter. Russell Frank Co now owns 66,506 shares of the company’s stock valued at $1,933,000 after buying an additional 7,498 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. raised its position in Repligen Corp. by 157.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 102,105 shares of the company’s stock valued at $2,888,000 after buying an additional 62,405 shares during the period.

Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.